SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract 2009

Rev Esp Quimioter 2009;22(1):34-37

Viral Load in Spanish HIV patients: trends since the introduction of HAART

J. M.ª Eiros ,  E. Sánchez-Padilla ,  F. J. Luquero ,  B. Nogueira ,  S. Rojo ,  J. Atienza-Herrero y R. Ortiz de Lejarazu 

  

The aim of this study is to describe trends in the percentage of samples with undetectable HIV viral load in Spain after the implementation of HAART. A descriptive observational study of HIV-VL measurements carried out in the microbiology department of the Hospital Clínico Universitario de Valladolid (HCUV) was conducted over a 9-year period (1996-2004). Regarding the trend over the study period, the 30-39 years age group accounted for most of the samples, although the percentage decreased from 65.5 % to 59.6% over the study period. In contrast, the 40-49 years group increased from 9.1 % to 14.5 %. The preponderance of men, with percentages above 70 %, was observed during the whole period. Although the purpose of this treatment is to maintain undetectable viral loads, since 1999 more than 60% of nonfirst samples had detectable levels. Based on the results of the VL trend among HIV/AIDS patients observed in this study, a large number of patients maintain elevated detectable VL years after HAART was implemented. Although different factors may be the cause of this and should be delimited in future studies, the phenomenon observed demonstrates the usefulness of monitoring VL and analyzing its time trend to gain further knowledge about the therapeutic results and care of HIV patients as a whole, also serving as the basis for corrective measures.

  

Key words:HIV, Viral Load, HAART.

Rev Esp Quimioter 2009;22(1):34-37  [pdf] 

20 octubre, 2009/por csanchez
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 csanchez https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png csanchez2009-10-20 16:30:292009-10-20 16:30:29Rev Esp Quimioter 2009;22(1):34-37

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2009;22(1):34-37 Link to: Rev Esp Quimioter 2009;22(1):34-37 Rev Esp Quimioter 2009;22(1):34-37 Link to: Rev Esp Quimioter 2009;22(1):38-47 Link to: Rev Esp Quimioter 2009;22(1):38-47 Rev Esp Quimioter 2009;22(1):38-47
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba